
THE ARISING

Understanding Cholesterol



NOVEMBER 2026

Understanding Cholesterol

What the results mean, what can change, and why the whole person matters.

Start with a decision, not a grade

A cholesterol report can look like a school report card: numbers, ranges, and a few results marked high. It is tempting to ask only whether you passed.

A more useful question is what the results change. Do they help explain a family history of early heart disease? Do they support a different eating pattern, a medication discussion, or closer attention to another risk factor? Has someone already had a heart attack, or are we trying to prevent a first one?

Those situations are different. The same laboratory value does not automatically lead to the same decision for every person.

Cholesterol is necessary for normal biology. The concern is how cholesterol-carrying particles contribute to disease in artery walls over time, and how much of that risk can be reduced. The purpose of care is fewer heart attacks, strokes and other important problems, not merely a more attractive laboratory report. [1]

Several measurements, several questions

LDL cholesterol, often written LDL-C, describes the amount of cholesterol carried in LDL particles. It does not directly count those particles. LDL is often called “bad cholesterol,” but that shorthand can hide what the test actually measures.

Non-HDL cholesterol is total cholesterol minus HDL cholesterol. It includes cholesterol carried in several kinds of particles that can contribute to atherosclerosis, the buildup of disease in artery walls. It can add useful information beyond LDL-C alone. [1]

Apolipoprotein B, or apoB, is a protein carried on these artery-related particles. Its concentration helps estimate particle number. Sometimes the amount of cholesterol and the number of particles give different impressions of risk. In selected circumstances, apoB can help clarify that mismatch. It is not a test that every person needs simply because it is available. [1]

HDL cholesterol is another measurement on the usual panel. A high HDL result does not cancel out the risk associated with high LDL or other risk factors. The report is not a balance sheet in which one favorable number erases every unfavorable one.

Lipoprotein(a), or Lp(a), is different again: a largely inherited LDL-like particle with an additional protein attached. It is not separately measured by the ordinary LDL-C number. Current guidance recommends at least one measurement in adulthood. Our companion issue, The Inherited Risk, explains why its units and interpretation deserve their own discussion. [1]

These measurements overlap in what they tell us, but they are not interchangeable. More tests are useful when they answer a question that changes care.

The number sits inside a life

A person who has already had a cardiovascular event is considering prevention of another event. This is often called secondary prevention. A person without known cardiovascular disease is considering primary prevention: reducing the chance of a first event.

Age, blood pressure, smoking, diabetes, family history and other circumstances affect the overall picture. Someone's current risk and the consequences of continued exposure over time both matter. A lower short-term estimate does not mean that a markedly elevated LDL level can always be ignored.

The 2026 US dyslipidemia guideline uses the PREVENT risk framework to help guide primary-prevention discussions in adults aged 30–79. A risk calculator is a decision aid, not a prophecy. It cannot know everything about a person, and the result still needs to be interpreted with relevant clinical information. [1]

This is why one universal “perfect cholesterol number” is not a complete plan. The intensity of treatment and the LDL and non-HDL goals depend on the situation. Your clinician should be able to explain what the proposed target is intended to accomplish for you.

Lowering LDL has outcome evidence

An important distinction separates cholesterol care from simply chasing a blood marker: randomized trials have shown that lowering LDL with established treatments can reduce important cardiovascular events.

A large Cholesterol Treatment Trialists' analysis combined 27 randomized trials involving 174,149 participants. They compared statins with control treatment, or more-intensive with less-intensive statin treatment. For each reduction of about 1 mmol/L in LDL cholesterol, it found roughly a 21% relative reduction in major vascular events. The comparison included major coronary events, strokes and procedures to restore blood flow in coronary arteries. [2]

“Relative” is the word to notice. It does not mean that 21 out of every 100 people avoided an event. The absolute benefit depends on how likely an event was to occur in the first place.

Among the analysis's lower-risk participants, with an estimated five-year major vascular-event risk below 10%, lowering LDL by 1 mmol/L was associated with about 11 fewer major vascular events per 1,000 people over five years. That is about 1.1 percentage points, not 11 percentage points. It is a finding for those study populations, not a personal forecast for everyone reading this issue. [2]

Someone at higher risk can have a larger absolute benefit from a similar proportional reduction. The treatment burden, potential adverse effects and the person's preferences still belong in the decision.

Why evidence belongs to a treatment

The benefit is not confined to one way of lowering LDL. But evidence from one medicine cannot simply be assigned to every other medicine that changes the same laboratory result.

IMPROVE-IT studied 18,144 people after an acute coronary syndrome, such as a heart attack or unstable symptoms caused by reduced blood supply to the heart. Researchers compared adding ezetimibe to simvastatin with simvastatin alone. Its combined outcome included cardiovascular death, a nonfatal heart attack, unstable angina requiring rehospitalization, coronary revascularization at least 30 days after

randomization, or a nonfatal stroke. Revascularization means a procedure to restore blood flow. The seven-year rates were Kaplan-Meier estimates, which account for differing follow-up rather than simply dividing the number of events by all enrolled participants. Those estimates were 32.7% versus 34.7%, an absolute difference of 2 percentage points. Median follow-up was six years. [3]

That illustrates a clinically meaningful question: does adding a particular treatment improve outcomes beyond the treatment already being used? It does not mean that every healthy person can expect the same benefit, or that every LDL-lowering product has completed the same test.

PCSK9-directed therapies require the same care in interpretation. Antibodies that block the PCSK9 protein and inclisiran, which reduces its production through an RNA-based mechanism, are not identical products with interchangeable evidence. A discussion should name the medicine, the population studied, the outcome measured and the practical burden.

The recent Lp(a) story is a useful reminder. A treatment can markedly change a blood marker without demonstrating the expected reduction in cardiovascular events. That does not invalidate established LDL trial evidence; it shows why the result for each treatment matters.

Statins can cause muscle symptoms and modestly increase diabetes risk. Rare serious muscle injury and interactions with other medicines also matter. Symptoms deserve assessment rather than dismissal; the expected benefit and possible harms should be considered together. [2]

Food is a pattern, not a single rescue ingredient

An eating pattern can support cardiovascular health without turning every meal into a calculation. The 2026 American Heart Association guidance emphasizes vegetables and fruit, whole grains, healthy protein sources and replacing saturated fats with unsaturated fats. It also supports attention to fiber, added sugars and sodium. [4]

Replacement is important. “Eat less fat” does not say what you will eat instead. Replacing some butter with an unsaturated plant oil is a different change from replacing a meal with refined starch and sugary snacks. The whole pattern is more informative than a single nutrient slogan.

Practical changes might include adding beans to a familiar dish, choosing a whole-grain option you enjoy, or making nuts, vegetables and fruit easier to reach. These are examples of applying a dietary pattern, not promises of a specific LDL reduction for every person.

A useful plan also fits budget, culture, appetite and the ability to shop and cook. A theoretically ideal menu that cannot be sustained may help less than a few workable changes repeated often.

Alcohol is not something to start for heart protection. And food changes need not become a contest between lifestyle and medicine. For some people, both are useful; for others, the next step is a conversation about what is realistic and sufficient. [4]

A lower glucose curve is not the same as lower cholesterol risk

A meal's effect on blood glucose answers a different question from its effect on LDL cholesterol, nutrition or long-term cardiovascular risk. Adding a great deal of saturated fat may change a glucose response without making the overall pattern more heart-healthy.

This matters as continuous glucose monitors become more visible outside diabetes care. A smooth line is not a complete score for a food or a person's health. Glycemic index, glucose response, LDL cholesterol and Lp(a) should help answer their own questions rather than compete to become the only number that matters.

The useful connection is a broader one: a sustainable pattern of food, movement and appropriate clinical care can address several risks together, while each test retains its limits.

Make the next conversation concrete

You do not need to memorize every abbreviation. Bring the actual report, your current medicines and the questions that matter most.

• What do LDL-C, non-HDL-C and the other results tell us in my situation?

• Are we preventing a first event or another event?

• Would apoB or Lp(a) answer a question we have not already answered?

• What benefit is realistic in absolute terms, and over what period?

• What adverse effects, interactions or treatment burdens should we discuss?

• Which food changes are most useful and practical for me?

• When will we check whether the plan is working?

Do not stop or alter a prescribed medicine because of one general article. If a treatment is difficult to tolerate, that is a reason to discuss the problem and options, not a reason to remain silent.

A cholesterol result is a starting point. The aim is a plan that connects evidence to your risks, your preferences and the life you want to keep living.

Sources and further reading

[1] Blumenthal RS, Morris PB, Gaudino M, et al. 2026 ACC/AHA multisociety guideline on the management of dyslipidemia. *Circulation*. 2026;153:e1154–e1276. Publication. Official summary.

[2] Cholesterol Treatment Trialists' Collaborators, Mihaylova B, Emberson J, et al. Effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. *Lancet*. 2012;380:581–590. Publication. Full text.

[3] Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. *New England Journal of Medicine*. 2015. Publication.

[4] Lichtenstein AH, Khera A, Anderson CAM, et al. 2026 Dietary Guidance to Improve Cardiovascular Health. Publication. Official summary.

The CTT synthesis received public and charitable funding, including support from the British Heart Foundation and Medical Research Council; contributing trials may have received industry funding. IMPROVE-IT was funded by Merck.